Drug Delivery Market Share Report | Global Outlook 2023-2028

[Research Report] The drug delivery market size is expected to grow from US$ 20,99,856.7 million in 2022 to US$ 32,54,594.2 million by 2028; it is estimated to record a CAGR of 7.7% from 2023 to 2028.

The drug delivery market is segmented based on route of administration, distribution channel, end user, and geography. The report offers insights and in-depth market analysis, emphasizing parameters such as drivers, trends, opportunities, and competitive landscape analysis of leading market players across various regions. It also includes analyses of the impact of the COVID-19 pandemic across major regions.

Strategic Insights

Market Insights

Growing Demand for Noninvasive Drug Delivery Systems Drives Drug Delivery Market

Noninvasive drug delivery generally refers to methods of painless drug delivery across the biological barriers of mucosal surfaces or skin. This drug delivery method could lead to improved access to medicines, adherence to treatment regimes, and better drug safety profiles. Patients prefer noninvasive drug delivery routes due to such apparent advantages over injection-based drug administration. Patient compliance has been found to be much higher when drugs are administrated by noninvasive methods, as they experience decreased pain during the procedure. With improvements in medical devices and transdermal delivery technologies, the noninvasive mode of drug delivery is now ready to compete with traditional methods of oral and injectable routes of drug delivery. Topical, transdermal-active (device-aided enhanced penetration), transdermal-passive, trans-ocular membrane, trans-mucosal membrane, and delivery via an alveolar membrane from inhaled medication are a few of the popular noninvasive drug delivery methods.

A low rejection rate, ease of administration, convenience, and durability make TDDS the most attractive method of drug delivery. In addition to pharmaceutical administration in medical facilities, TDDS could be used in different procedures in the skincare industry. Since this method mainly involves local administration, it can prevent nonspecific delivery to tissues that are not targeted by the drug. Developments in TDDS are likely to help control the prevalence of cardiovascular and central nervous system disorders, genetic disorders, diabetes, neuromuscular disorders, and infectious (including localized conditions) diseases while driving advancements in vaccination and patient preference for self-administration of drugs for long-term treatment.

Drug delivery through noninvasive methods involves reduced dosing frequency and simplified dosing schedules. Moreover, these delivery systems can significantly reduce the cost of clinical use as patients can self-administer drugs via these methods. In many cases, the manufacturing cost of drugs with noninvasive delivery systems is lesser than the production costs of injections. For instance, inhaled insulin has emerged as a well-tolerated and preferred modality for treating diabetes. Thus, the growing demand for noninvasive drug delivery systems propels the growth of the drug delivery market.

Route of Administration-Based Insights

Based on the route of administration, the drug delivery market is segmented into oral drug delivery, injectable drug delivery, transmucosal drug delivery, topical drug delivery, implantable drug delivery, and ocular drug delivery. In 2022, the injectable drug delivery segment held the largest share of the drug delivery market. However, the topical drug delivery segment is anticipated to register the highest CAGR during the forecast period. Injectable drug delivery is considered one of the effective routes of drug administration due to the speed and effectiveness of delivery to the target site and improved patient experience. The injections help administer drugs, vaccines, or any other therapeutic agents into the body. The drug delivery technique via a route other than the digestive tract is termed parenteral. The parenteral route of administration includes intramuscular, subcutaneous, and intravenous. The development of needle-free injectors has improved insulin drug delivery by reducing the risk of needlestick injuries in diabetic patients.

Increasing usage of injections in complex drug delivery procedures due to advancements in injectable drug delivery systems and the introduction of next-generation injectable devices with superior functional capabilities enhance the global drug delivery market growth for the injectable drug delivery segment.

Drug Delivery Market, by Route of Administration– 2022–2028

Get more information on this report : Request Free Sample PDF

Based on distribution channel, the drug delivery market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2022 and is expected to record the highest CAGR during the forecast period.

End User-Based Insights

Based on end user, the drug delivery market is segmented into hospitals and clinics, home care settings, and other end user. The hospitals and clinics segment accounted for the largest market share in 2022 and is projected to record the highest CAGR during the forecast period.

The drug delivery market players adopt organic strategies such as product launch and expansion to expand their geographic footprint and product portfolios and meet the growing demands. Inorganic growth strategies adopted by market players allow them to expand their businesses and enhance their geographic presence. Additionally, these growth strategies help companies strengthen their clientele and enlarge their product portfolios.

• In September 2022, Becton, Dickinson, and Company introduced a next-generation glass pre-fillable syringe (PFS) and set a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, contamination, and integrity. The new BD Effivax glass pre-fillable syringe has been designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing.
• In June 2022, Pfizer Inc. strengthen its commitment to United States manufacturing with a US$120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVID (nirmatrelvir tablets and ritonavir tablets). The investment expanded the production of active pharmaceutical ingredients (API) and registered starting materials (RSMs) used to manufacture nirmatrelvir.

Company Profiles

• Becton Dickinson and Co             
• Novo Nordisk AS
• Johnson & Johnson                     
• Boston Scientific Corp
• Pfizer Inc.                                
• Baxter International Inc               
• Gerresheimer AG                       
• Kindeva Drug Delivery LP            
• GlaxoSmithKline Plc                    
• Bausch Health Companies            
• Novartis AG                              
• Sever Pharma Solutions
• Boehringer Ingelheim International